Elanco Animal Health is a U.S.-based animal health company that develops and sells medicines, vaccines, feed additives and related services for pets and farm animals. Its portfolio spans dogs and cats as well as cattle, poultry, swine and sheep, with sales in more than 90 countries through veterinarians, distributors, retailers and farm producers.
55,0 %
−4,9 %
+6,2 %
2.17
1.08
| % | |
|---|---|
| Pet Health | 45% Products sold for dogs and cats, including flea, tick and other companion-animal therapies. |
| Farm Animal Health | 50% Products for cattle, poultry, swine and sheep used to prevent and treat disease and improve productivity. |
| Feed Additives and Sustainability Solutions | 3% Products such as Bovaer that support animal performance and emissions reduction in livestock systems. |
| Veterinary Services and Support | 2% Scientific consulting, training, education and data analytics offered alongside product sales. |
Elanco sells to a mix of distributors, retailers, veterinarians and direct farm producers, so its demand is split...
Buy companion-animal products and some farm animal therapies, and influence product choice through prescribing and education.
Purchase pet health products for resale through clinic, retail and e-commerce channels.
Beef, dairy, pork and poultry operations buy products to prevent disease and improve productivity.
End customers for flea, tick and other companion-animal products, usually reached indirectly through vets and retailers.
Large purchasing organizations that negotiate pricing and can pressure margins.
Elanco sells its portfolio in more than 90 countries, making it a globally diversified animal-health business rather...
Elanco’s strategy centers on revenue growth through portfolio development, product innovation and lifecycle management...
New molecules, registrations and indications are needed to offset mature brands and sustain growth.
Top products contribute a large share of revenue, so extending their commercial life protects the base business.
Pet health demand is shifting toward retail and e-commerce, so channel coverage is critical to preserve share.
Elanco faces competitive pressure, regulatory risk and channel disruption risk because its products depend on...
Advantage Family, Seresto, Credelio Family, Rumensin and Maxiban/Monteban represented a large share of revenue, so any loss of demand or patent protection would be meaningful.
New products and new indications require approvals and can face delays, warning labels or adoption setbacks.
Pet owners increasingly buy through online, big-box and specialty channels, which can lower margins and weaken clinic-based sales.
Larger buying groups can use scale to negotiate lower prices and reduce Elanco’s margins.
International farm-animal demand can be pulled forward or delayed by tariff expectations and policy changes.
: 28.4.2026